Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2020

View Archived Issues

'Undruggable' phosphatase can be targeted for dystrophies

New phase II study evaluates inhaled ensifentrine in hospitalized patients with COVID-19

Chewing the fat keeps stem cells quiet

FDA accepts IND for ABP-450 as a treatment for cervical dystonia

ESsCOVID study of trimodulin in patients with COVID-19 receives approval in Spain

University of California patents lentiviral vectors for hemoglobinopathies

Spanish researchers identify new SFRP1-targeting antibodies for Alzheimer's disease

Astellas Pharma presents new CXC3-CL1-encoding AAV vectors for retinal degeneration

Beijing Sanyou Liheze Biological Technology discovers potential stem cell therapy for COPD

New OX40-targeting antibodies presented by Zhengzhou Airport Baiqiao Biotechnology

Two gut bacteria combine to exacerbate MS symptoms

Akebia reports topline data from its PRO2TECT global phase III program of vadadustat

Researchers identify new cardiac syndrome tied to deletion of chromosome locus 4q25

Enrollment opens in phase I study of LY-3410738 in advanced solid tumors with IDH1 mutations

Relay begins first-in-human evaluation of FGFR2 inhibitor RLY-4008

Increased expression of MUDENG linked to accelerated liver fibrosis in mice

City of Hope tests leflunomide in cancer patients with COVID-19

Savara ends exploratory study of Molgradex for nontuberculous mycobacterial lung infection in CF

BIO89-100 enters phase II trial for severe hypertriglyceridemia

Auris advances phase II trial of intranasal betahistine for vertigo

Clear Creek Bio starts phase I study of brequinar for treatment of COVID-19

Orca Bio and Lyell partner on next-generation T-cell therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...